| Outcome |
Relative effect
(95% CI) |
Absolute effect
(95% CI)1 |
Certainty of the Evidence
(GRADE) |
Clinical improvement
D28 |
RR: 1.08
(0.76 - 1.53) |
57 more per 1000
(from 171 fewer to 378 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious
Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 2 trials
Han MK, 2022; Incyte Corporation 2022
643 participants
|
|
Ruxolitinib
771 per 1,000
(542 - 1000) |
Placebo
714
per 1,000 |
|
Clinical improvement
D60 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above)
D28 |
RR: 1.01
(0.58 - 1.75) |
1 more per 1000
(from 49 fewer to 88 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious
Multicentre study conducted across several countries, therefore not downgraded for indirectness Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 1 trials
Han MK, 2022
432 participants
|
|
Ruxolitinib
118 per 1,000
(68 - 205) |
Placebo
117
per 1,000 |
|
WHO progression score (level 7 or above)
D60 |
Outcome not yet measured or reported
|
|
All-cause mortality
D28 |
RR: 0.79
(0.48 - 1.27) |
43 fewer per 1000
(from 106 fewer to 55 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious
Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 2 trials
Han MK, 2022; Incyte Corporation 2022
643 participants
|
|
Ruxolitinib
160 per 1,000
(98 - 258) |
Placebo
203
per 1,000 |
|
All-cause mortality
D60 |
Outcome not yet measured or reported
|
|
Viral negative conversion
D7 |
Outcome not yet measured or reported
|
|
Adverse events
|
RR: 1.01
(0.85 - 1.19) |
7 more per 1000
(from 98 fewer to 124 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious
Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 2 trials
Han MK, 2022; Incyte Corporation 2022
643 participants
|
|
Ruxolitinib
658 per 1,000
(553 - 775) |
Placebo
651
per 1,000 |
|
Serious adverse events
|
RR: 1.09
(0.73 - 1.65) |
12 more per 1000
(from 37 fewer to 88 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 2 trials
Han MK, 2022; Incyte Corporation 2022
643 participants
|
|
Ruxolitinib
148 per 1,000
(99 - 223) |
Placebo
135
per 1,000 |
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
